澳门老奇人论坛

Meeting Coverage >

GuCS

Enfortumab Vedotin Promising in Neovadjuvant Therapy in Advanced Bladder Cancer

Early-phase study offers 36% pCR in cisplatin-ineligible patients with muscle-invasive disease

Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer

Docetaxel-enzalutamide regimen may offer another option for men who progressed on AR inhibitor

Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPC

In one case, rPFS benefit was seen regardless of HRR mutational status

Darolutamide Improves OS in Metastatic Prostate Cancer

The AR inhibitor plus standard therapy led to a 32% reduced risk of death versus placebo

A CLEAR Upfront Winner in Advanced RCC?

Pembrolizumab-lenvatinib makes splash with longest PFS benefit in RCC recorded to date

Practice-Changing Trial in Metastatic Papillary RCC

Cabozantinib improved PFS, response rates over sunitinib

New Standard in High-Risk Muscle-Invasive Bladder Cancer?

Adjuvant nivolumab improves DFS in all comers, PD-L1 population

CCR Score Could Offer ADT-Free Path in Higher-Risk Prostate Cancer

Large proportion of intermediate- to high-risk patients could avoid aggressive therapy

Survival Boost in Bladder Cancer With Antibody-Drug Conjugate

Four-month absolute improvement with enfortumab vedotin in previously treated disease

Radionuclide Tx Wins in Third-Line Metastatic CRPC

Early trial shows improved PFS, response rates versus cabazitaxel

Hit and Miss in Castration-Resistant Prostate Cancer

No OS benefit with apalutamide-abiraterone, despite improved PFS

No Survival Bump Yet with Tivozanib for RCC

Selected studies on kidney cancer from the Genitourinary Cancers Symposium

'Encouraging' Early Data with Keytruda in High-Risk Bladder Ca

Will responses in non-muscle-invasive, BCG-unresponsive disease prove durable?

Bladder Ca Treatment Enters 'Post-Checkpoint' Era

Early trials show responses with antibody-drug conjugates

Doubling Down on Antiandrogens Improves PFS in Metastatic Prostate Ca

But lack of OS data for enzalutamide-ADT may hold it back

Immunotherapy Lurches Forward in Prostate Cancer

Combination trials in mCRPC yield responses in immunologically "cold" tumor

Surveillance of Low-Risk Prostate Cancer Tripled

Radical prostatectomy gained some ground for high-risk disease

Radiological Agent Shows Promise in Heavily Treated mCRPC

PSA decline of 50% or greater in two-thirds of patients

Better Survival for African-Americans With mCRPC

Significant improvement vs whites with androgen-directed agents

Survival Bump in Bladder Cancer with Keytruda

But no outcome advantage for Tecentriq in metastatic urothelial cancer

Time to Metastasis Prolonged in Castration-Resistant Prostate Ca

Researchers found a 22-month improvement with enzalutamide

Apalutamide Slows Metastasis in Prostate Cancer

Two-year delay in metastatic progression with apalutamide

Gene Therapy Moves Ahead in Urothelial Cancer

Complete response in 35% of BCG-treated patients at 12 months

'Jurassic' Clinical Trial Yields Prostate Cancer Guidance

Negative trial informs new studies of adjuvant therapy

Cancer Drugs' Benefit Continues After Drug Stopped

Response for as long as 20 months after PD-1/PD-L1 stopped

Antibiotics May Damper Effect of PD-1/PD-L1 Blockade

Worse PFS in metastatic renal cell carcinoma

No DFS Benefit With Chemoradiation in Bladder Cancer

Adjuvant combo reduces local recurrence after cystectomy

Adding Hormonal Tx To Salvage RT Ups Prostate Ca Survival

Metastasis, cancer-specific survival also reduced in high-risk disease

Lower-Dose RT New Standard for Prostate Cancer?

Non-inferiority demonstrated for 60 Gy versus 74 Gy

Aspirin May Lower Risk of Lethal Prostate Cancer

But confirmation needed before a firm recommendation can be made

Seeds Top EBRT as Boost Tx in Prostate Cancer

And other advances in prostate cancer care from the Genitourinary Cancers Symposium.

Zytiga Prolongs Prostate Cancer Survival

ORLANDO -- Survival improved and disease progression slowed in men with metastatic castration-resistant prostate cancer treated in first line with abiraterone acetate (Zytiga).

Steroids Reduce Benefits of Prostate Ca Tx

ORLANDO -- Men with castration-resistant prostate cancer had worse survival when treated with corticosteroids, regardless of their primary treatment, a post-hoc analysis of a randomized trial showed.

Early Radiation Boosts Prostate Cancer Survival

ORLANDO -- Immediate radiation therapy after radical prostatectomy led to a 50% increase in long-term biochemical progression-free survival for patients with locally advanced prostate cancer, according to a study reported here.